Background: Strontium-89 is a pure Beta-emitting radioactive analogue of calcium that has been shown to be beneficial in the palliation of pain due to osseous metastases from adenocarcinoma of the prostate. The most significant reported toxicity is dose-related, reversible, myelosuppression characterized primarily by thrombocytopenia.
Methods: A report of two patients in whom acute myelogenous leukemia (AML) developed after treatment with strontium-89 and a review of the literature are presented.
Results: The two patients described in the current study developed AML 17 months and 26 months, respectively, after exposure to strontium-89 for the treatment of prostate carcinoma. To the authors' knowledge these patients represent the first two reported cases of AML after strontium-89 therapy for prostate carcinoma.
Conclusions: The results of the current study suggest the leukemogenic potential of strontium-89 treatment in humans. To the authors' knowledge, the current study represents the first report of AML after therapeutic exposure to strontium-89. As this agent is used more frequently (and earlier in the disease course) in patients with prostate carcinoma, an increased incidence of secondary AML complicating the clinical management of patients with prostate carcinoma may be observed. [See editorial on pages 497-9, this issue.]
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/(sici)1097-0142(20000201)88:3<620::aid-cncr19>3.0.co;2-# | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Tumori
October 2019
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture, Italy.
Radium-223 dichloride (Ra) is the first, recently approved, α-particle-emitting radiopharmaceutical for the treatment of patients with bone metastases in castration-resistant prostate cancer (CRPC) and no evidence of visceral metastases. We explored MEDLINE, relevant congresses, and websites for data on Ra and prostate cancer therapies, focusing on therapeutic strategies and timing, bone metastases, and diagnostic assessment. Ra represents the only bone-targeting agent that has significantly extended patients' overall survival while reducing pain and symptomatic skeletal events.
View Article and Find Full Text PDFThe potential for disease initiation by inhaled beta-emitting nuclear particles.
Med Hypotheses
July 2018
Abd Consultant, 517 Bear Cub Lane, Lake Placid, NY 12946, United States. Electronic address:
There were many anecdotal reports of injuries to humans, animals and plants following the Three Mile Island, Chernobyl and Fukushima accidents that were indicative of radiation exposures that delivered a dose of at least 0.5 Sieverts, but studies that attempted to relate observed increases of cancer rates and other injuries with exposure to the radioactive releases from these accidents have failed to find an association. To resolve this dissonance, it was assumed that an analysis of knowledge about accident releases and health effects gathered from one of these accidents could lead to the identification of an unrecognized exposure that could be inferred to have caused a specific observed injury that required a dose of at least 0.
View Article and Find Full Text PDFAfter some therapeutic nuclear medicine procedures with unsealed radionuclides, precautions may be needed to limit doses to other people, but this is rarely the case after diagnostic procedures. Iodine-131 results in the largest dose to medical staff, the public caregivers, and relatives. Other radionuclides used in therapy are usually simple beta emitters (e.
View Article and Find Full Text PDFAcute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostate.
Cancer
February 2000
Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Cornell University Medical College, New York, NY 10021, USA.
Background: Strontium-89 is a pure Beta-emitting radioactive analogue of calcium that has been shown to be beneficial in the palliation of pain due to osseous metastases from adenocarcinoma of the prostate. The most significant reported toxicity is dose-related, reversible, myelosuppression characterized primarily by thrombocytopenia.
Methods: A report of two patients in whom acute myelogenous leukemia (AML) developed after treatment with strontium-89 and a review of the literature are presented.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!